Cardiothoracic & vascular anesthesia

Effect of a Machine Learning-Derived Early Warning Tool With Treatment Protocol on Hypotension During Cardiac Surgery and ICU Stay: The Hypotension Prediction 2 (HYPE-2) Randomized Clinical Trial

Crit Care MedPublished Randomised controlled trial

Primary resultResult — go to the resultMedian of differences −0.40 mm Hg 95% CI −0.65 to −0.27

Authors' conclusion

Using HPI combined with diagnostic guidance on top of standard care significantly decreased hypotension severity in elective cardiac surgery patients compared with standard care.

Study context

Population
Adults undergoing elective on-pump CABG, with or without single heart valve surgery, with mean arterial pressure (MAP) target ≥65 mm Hg during off-pump phases and ICU stay; academic hospital, the Netherlands130 in primary analysis
Participants
142 adults
Comparison
Hypotension Prediction Index (HPI) with diagnostic guidance plus standard care vs standard care alone
  • HPIn = 72
  • Standard caren = 70reference
Primary endpoint
Severity of hypotension: time-weighted average (TWA) of MAP <65 mm Hg
Methodological detailssingle-centre
  • Single-centre

Primary result

As reported in the abstract

Median of differences

−0.40 mm Hg

95% CI −0.65 to −0.27

P < 0.001

HPI vs Standard care
median of differences −0.40 mm Hg (95% CI −0.65 to −0.27); P < 0.001

Secondary outcomes

Time in hypotension · less time in hypotension · per-group values are measurement duration

median (minutes) 28 (17–44)

Hypertension severity, treatment choice, fluid, vasopressor and inotrope amounts

No significant differences

Original publication

Effect of a Machine Learning-Derived Early Warning Tool With Treatment Protocol on Hypotension During Cardiac Surgery and ICU Stay: The Hypotension Prediction 2 (HYPE-2) Randomized Clinical Trial. Crit Care Med. Published 22 November 2024. doi:10.1097/ccm.0000000000006518

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.